A comparison of XXXX with @entity12833 in pregnancy induced @entity101 .

@entity1 @entity12833 @entity101 @entity594
OBJECTIVE: To compare @entity594 (group 1) with @entity12833 (group 2) in the management of pregnancy induced @entity101 (PIH). DESIGN: A prospective clinical trial. SETTING: Obstetric Unit, General Hospital, Peradeniya. @entity1 : A total of 126 @entity1 with PIH were allocated alternately to either group. The @entity1 in group 1 received @entity594 30 to 90 mg/day and in group 2 @entity12833 750 to 2000 mg/day. MEASUREMENTS: Blood pressure, the extra days added to the pregnancy, number of @entity1 treated for acute @entity101 episodes, maturity of fetus at birth, mode of delivery, birth weight, intrauterine deaths, Apgar score, maternal side effects and complications. RESULTS: The two groups on admission to the study had similar periods of gestation (group 1, 33.6 + 5.9, group 2, 34.1 + 4.2), systolic blood pressure in mmHg (151 + 22, and 154 + 24) and diastolic blood pressure (108 + 12, and 108 + 12). The results showed no differences between the two groups, with respect to maturity of fetus at delivery (35.1 + 5.5, and 35.7 + 2.9), mode of delivery, number of intrauterine deaths, average systolic blood pressure in mmHg (148 + 14 and 152 + 16), average diastolic blood pressure (102 + 8 and 104 + 9), highest systolic blood pressure (169 + 24 and 167 + 30), highest diastolic blood pressure (115 + 12 and 116 + 11), birth weight in kg (2.015 + 0.957, and 1.922 + 0.660) and number of days added to the pregnancy (7 + 7, 9 + 11). The Apgar score for group 2 was better than in group 1, and less @entity1 in group 2 required treatment for acute @entity101 during the period of study. CONCLUSIONS: The results of our study indicate that @entity594 is as effective as @entity12833 in the treatment of PIH.
